Search in:

Acta Oncologica Volume 56, 2017 - Issue 9

Journal homepage

Free access

1,401

Views

CrossRef citations to date

Altmetric

LETTERS TO THE EDITOR

Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal

Floor J. E. LubbermanDepartment of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands;

Nielka P. van ErpDepartment of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands;

Rob ter HeineDepartment of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands;

Carla M. L. van HerpenDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, The NetherlandsCorrespondence[email protected]

Pages 1238-1240 | Received 23 Feb 2017, Accepted 18 Mar 2017, Published online: 07 Apr 2017

Cite this article
https://doi.org/10.1080/0284186X.2017.1311024
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions
View PDF PDF

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (15)

Joanneke K. Overbeek, Niels A.D. Guchelaar, Ma Ida Mohmaed Ali, Petronella B. Ottevanger, Haiko J. Bloemendal, Stijn L.W. Koolen, Ron H.J. Mathijssen, Ingrid A. Boere, Paul Hamberg, Alwin D.R. Huitema, Gabe S. Sonke, Frans L. Opdam, Rob ter Heine & Nielka P. van Erp. (2023) Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study). European Journal of Cancer 194, pages 113346.
Crossref

Susan Hofman, Daan J. Touw, Bart F. R. SpanThijs H. Oude Munnink. (2023) Cobicistat as a Potential Booster of Ponatinib and Dasatinib Exposure in a CML Patient: A Case Study. Therapeutic Drug Monitoring 45:4, pages 428-430.
Crossref

Niels Westra, Daan Touw, Marjolijn Lub-de Hooge, Jos Kosterink & Thijs Oude Munnink. (2023) Pharmacokinetic Boosting of Kinase Inhibitors. Pharmaceutics 15:4, pages 1149.
Crossref

J.K. Overbeek, R. ter Heine, H.M.W. Verheul, E. Chatelut, M.A. Rudek, H. Gurney, R. Plummer, D.C. Gilbert, T. Buclin, D.M. Burger, H.J. Bloemendal & N.P. van Erp. (2023) Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs. ESMO Open 8:1, pages 100749.
Crossref

Ard van Veelen, Judith Gulikers, Lizza E.L. Hendriks, Safiye Dursun, Juanita Ippel, Egbert F. Smit, Anne-Marie C. Dingemans, Robin van Geel & Sander Croes. (2022) Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial. Lung Cancer 171, pages 97-102.
Crossref

René J. Boosman, Cornedine J. de Gooijer, Stefanie L. Groenland, Jacobus A. Burgers, Paul Baas, Vincent van der Noort, Jos H. Beijnen, Alwin D.R. Huitema & Neeltje Steeghs. (2022) Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib. Pharmaceutical Research 39:4, pages 669-676.
Crossref

Simon E. Koele, Stijn W. Beek, Anthonie J. Wekken, Berber Piet, Michel M. Heuvel & Rob Heine. (2021) Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients. British Journal of Clinical Pharmacology 88:4, pages 1930-1934.
Crossref

Stefanie D. Krens, Sasja F. Mulder & Nielka P. van Erp. (2021) Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites. Cancer Chemotherapy and Pharmacology 89:2, pages 271-274.
Crossref

Eric D. Eisenmann, Zahra Talebi, Alex Sparreboom & Sharyn D. Baker. (2021) Boosting the oral bioavailability of anticancer drugs through intentional drug–drug interactions. Basic & Clinical Pharmacology & Toxicology 130:S1, pages 23-35.
Crossref

Eric D. Eisenmann, Qiang Fu, Elizabeth M. Muhowski, Yan Jin, Muhammad Erfan Uddin, Dominique A. Garrison, Robert H. Weber, Jennifer A. Woyach, John C. Byrd, Alex Sparreboom & Sharyn D. Baker. (2021) Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition. Cancer Research Communications 1:2, pages 79-89.
Crossref

Masahide Fukudo, Gaku Tamaki, Makoto Azumi, Hidehiro Kakizaki, Seiji Matsumoto & Yoshikazu Tasaki. (2020) Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma. Investigational New Drugs 39:2, pages 595-604.
Crossref

Nicolas Hohmann, Farastuk Bozorgmehr, Petros Christopoulos, Gerd Mikus, Antje Blank, Jürgen Burhenne, Michael Thomas & Walter E. Haefeli. (2020) Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat. Clinical and Translational Science 14:2, pages 487-491.
Crossref

David M. Burger, Alexandra Calmy & Catia Marzolini. (2020) Cobicistat: A case of mislabelled drug‐drug interaction risk?. British Journal of Clinical Pharmacology 86:5, pages 834-836.
Crossref

G. Beinse, A. Hulin & Benoit Rousseau. (2019) Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma. Investigational New Drugs 37:6, pages 1289-1291.
Crossref

. (2018) HIV-Associated Cancers and Related Diseases. New England Journal of Medicine 378:22, pages 2144-2145.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal

Articles from other publishers (15)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal

Citations (15)

Articles from other publishers (15)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date